Pediatric Hematology & Stem Cell Transplant

World-Leading Pediatric Hematology

Led by Professor Sun Yuan, Hospital Director and Head of Hematology-Oncology, and Professor Wu Minyuan, distinguished expert with State Council Special Contribution, our department is one of China's leading centers for childhood blood disorders.

The department is organized as a complete care system rather than a single ward:

Two general wards: Ward 7 for solid tumours, and Ward 8 for transplantation and general blood disorders
Two dedicated transplant units with 19 ISO Class 5 cleanrooms
150 beds, plus a hematology outpatient clinic, a PICC clinic, and a comfort-care treatment room
800m² central laboratory for research and clinical support
Designated stem cell transplantation center under Beijing's basic medical insurance, and partner hospital of the China Marrow Donor Program

80-90%

Leukemia Cure Rate

900+

Transplants Completed

14 Days

Donor Identification

73.7%

5-Year OS (Primary HLH)

🩹

Haploidentical HSCT

Parents or relatives with only 50% HLA compatibility can serve as donors. Our groundbreaking research on modified haploidentical transplantation pretreatment for primary HLH achieved a 2-year overall survival rate of 78.4% and 5-year rate of 73.7%.

Conditions We Treat

⚠️

Leukemia & Lymphoma

Acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), lymphoma, and relapsed or refractory cases. Cure rates from 80% to 90% for specific subtypes.

🩹

Hemophagocytic Syndrome (HLH)

Primary and secondary HLH with groundbreaking treatment protocols. Modified haploidentical transplant achieving industry-leading survival rates. More than 100 transplants performed for refractory or relapsed HLH.

🦠

Chronic Active EBV Infection

Most children recover from Epstein-Barr virus within weeks. In a small number, the virus stays active and keeps damaging organs. This persistent form is rare and needs specialist long-term care.

💊

Bone Marrow Failure

Acquired aplastic anaemia, Shwachman-Diamond syndrome, Fanconi anaemia, congenital neutropenia, Diamond-Blackfan anaemia, and dyskeratosis congenita.

🧠

Thalassemia

Comprehensive thalassemia treatment including stem cell transplantation as curative therapy. Expert in both matched and haploidentical transplants.

💪

Primary Immunodeficiency (PID)

Wiskott-Aldrich syndrome, severe combined immunodeficiency, very early onset inflammatory bowel disease, hyper-IgM syndrome, hyper-IgE syndrome, and chronic granulomatous disease.

🧪

Inherited Metabolic Disorders

Gaucher disease, Niemann-Pick disease, mucopolysaccharidosis, adrenoleukodystrophy, and metachromatic leukodystrophy — conditions in which healthy donor cells can replace the faulty ones.

🌱

Solid Tumours

Neuroblastoma, hepatoblastoma, Wilms tumour, retinoblastoma, atypical teratoid and rhabdoid tumours, germ cell tumours, and medulloblastoma.

Advanced Therapies

CAR-T Cell Therapy

Chimeric Antigen Receptor T-cell therapy for relapsed/refractory B-cell leukemia and lymphoma. Cutting-edge immunotherapy offering hope when conventional treatments fail.

CIK & NK Cell Therapy

Cytokine-Induced Killer cells and Natural Killer cell therapies providing additional treatment options for blood cancers, particularly in combination with transplantation.

Cord Blood Transplantation

Advanced cord blood transplant technology with the "Square of Life" approach. Effective for patients without matched sibling or unrelated donors.

Gene Therapy & Targeted Therapy

Precision medicine approach using gene sequencing for diagnosis and targeted therapy for specific genetic mutations in blood disorders and rare diseases.

Transplant Outcomes

More than 900 stem cell transplants — and the experience behind them.

900+

Transplants completed since the department opened

~100

Stem cell transplants performed each year

Over 1/2

Performed for HLH, chronic active EBV or immunodeficiency

2 months

Youngest transplant recipient

Three disease groups account for more than half of all transplants: hemophagocytic lymphohistiocytosis, chronic active Epstein-Barr virus infection, and primary immunodeficiency. The department has performed more than 100 transplants for refractory or relapsed HLH, nearly 50 for chronic active EBV infection, and nearly 100 for primary immunodeficiency. More than 80 percent of the children treated here are high-risk cases, and many reach transplantation only after new chemotherapy or targeted regimens bring their disease back under control.

Very young patients are another area of depth. Ten children transplanted here were under one year old and 32 were between one and two years old; the youngest recipient was two months old, and the youngest stem cell donor was nine months old. Repeated transplantation is also possible — by late 2025 the team had completed a third stem cell transplant for a fourth child. Older girls can have ovarian tissue preserved before transplantation so that surviving their disease does not mean losing the chance of having children later; 59 such procedures had been completed by the end of 2025.

Milestones

2015

The hospital is approved to perform stem cell transplantation, and the first hematology and transplant wards open.

2017

The center completes its 100th transplant; a nine-month-old donor provides stem cells for a two-year-old recipient.

2018

The second transplant unit opens with 19 ISO Class 5 cleanrooms, and national research groups on HLH transplantation and on autologous cord blood transplantation are founded with the department as lead unit.

2019

The International Medical Center opens and admits its first international referral.

2020

The solid tumour ward opens, and China's first third transplant for severe congenital neutropenia is completed.

2023

The youngest ovarian tissue cryopreservation in Asia is performed for a seven-month-old girl with leukaemia before her transplant.

2024

A joint clinic for Shwachman-Diamond syndrome opens, giving children with this rare inherited condition a single place for diagnosis, treatment and follow-up.

2025

The 14th transplant for PI3K-delta activation syndrome and the 28th transplant for Shwachman-Diamond syndrome are completed.

Meet Our Hematology Team

Thirteen specialists — including two professors based at international children's hospitals — care for every child in the department.

Sun Yuan

Hospital Director · Head of Hematology-Oncology

Haploidentical transplantation and HLH

Wu Minyuan

Chief Expert · Professor

Childhood leukemia treatment protocols

Wu Nanhai

Deputy Head, Hematology-Oncology

MDS, HLH and congenital neutropenia transplants

Tang Suoqin

Invited Expert · Professor

Blood diseases and solid tumours

Kejian Zhang

Professor, Cincinnati Children's Hospital

Molecular genetic diagnosis

Wang Jen-hsien

Visiting Professor

Infection control for immunocompromised children

Xu Zhongwei

Visiting Professor

CAR-T cell therapy

Liu Zhouyang

Head of Ward 8

Transplant ward · 1,000+ transplants

Xiao Juan

MD · Hematology

Leukemia, lymphoma and aplastic anaemia

Liu Hongyan

Head of Blood & Solid Tumour

Solid tumours and palliative care

Chen Jiao

Deputy Head, International Medical Department

Infant transplants and fertility protection

Jiang Fan

Associate Chief Physician

Hematology and traditional Chinese medicine

Fan Shifen

Attending Physician

HLH and chronic active EBV · 300+ transplants

Meet the Full Team →